title: Interaction of IFN alpha/beta with host cells essential to the early inhibition of Friend erythroleukemia visceral metastases in mice.
abstract: We have previously shown that an intact immune system was essential to the increase in survival time of IFN-alpha/beta-treated mice injected i.v. with an IFN-alpha/beta-resistant line of Friend erythroleukemia cells (FLC) highly metastatic to the liver and spleen. Here, we have investigated the early interactions of IFN alpha/beta with host cells prior to the development of the immune response. IFN alpha/beta treatment resulted in 50- to 100-fold inhibition of FLC multiplication in the liver and spleen of normal DBA/2 mice shortly after tumor inoculation, as evaluated by colony formation in agarose. IFN treatment was far less effective in inhibiting the multiplication of FLC in the livers of NK-cell-deficient DBA/2 beige mice, or in immunocompetent DBA/2 mice treated with antibody to asialo GMI, or silica, or in mice subjected to sub-lethal irradiation. Injection of antibody to CD4 or CD8 did not affect the early inhibitory action of IFN alpha/beta on FLC multiplication but did decrease survival time. Light- and electron-microscope examination of the livers of IFN-treated, FLC-injected mice confirmed the early inhibition of FLC multiplication in the liver and spleen. Our results indicate that IFN alpha/beta inhibits the development of FLC visceral metastases by acting first on host cells, such as NK cells and macrophages, and then continues to act in consort with the developing immune response.
authors.affiliation: Laboratory of Viral Oncology, CNRS, Villejuif, France.
authors.forename: I
authors.initials: I
authors.lastname: Gresser
authors.forename: T
authors.initials: T
authors.lastname: Kaido
authors.forename: C
authors.initials: C
authors.lastname: Maury
authors.forename: D
authors.initials: D
authors.lastname: Woodrow
authors.forename: J
authors.initials: J
authors.lastname: Moss
authors.forename: F
authors.initials: F
authors.lastname: Belardelli
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D015704:CD4 Antigens / Q000276:immunology; D016827:CD8 Antigens / Q000276:immunology; D002455:Cell Division / Q000187:drug effects; D005622:Friend murine leukemia virus; D005677:G(M1) Ganglioside / Q000276:immunology; D007370:Interferon Type I / Q000627:therapeutic use; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology* / Q000473:pathology* / Q000628:therapy; D008114:Liver Neoplasms, Experimental / Q000276:immunology / Q000517:prevention & control* / Q000556:secondary*; D051379:Mice; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D019335:Nitroarginine; D012822:Silicon Dioxide / Q000276:immunology; D013160:Splenic Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000556:secondary*
chemical_list: D000906:Antibodies; D015704:CD4 Antigens; D016827:CD8 Antigens; D007370:Interferon Type I; D019335:Nitroarginine; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside; D012822:Silicon Dioxide; D001120:Arginine